Floatz logo

mk-2206

Progesterone Receptor Negative

National Cancer Institute (NCI)Small moleculePhase 2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Progesterone Receptor Negative cohort.

Asset / SponsorPhaseRating
Carboplatin
Northwestern University
Phase 3BBB
Epirubicin
Massachusetts General Hospital
Phase 2BB
Pembrolizumab
Massachusetts General Hospital
Phase 2BB
Cyclophosphamide
Massachusetts General Hospital
Phase 3BB
Capecitabine
M.D. Anderson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

mk-2206 is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
diffuse large B-cell lymphomaDormant
B
Indicative ·
60 / 100
View asset →
prostate cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →